### Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of	entity
---------	--------

Circadian Technologies Limited

#### **ABN**

32 006 340 567

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

+Class of +securities issued or to be issued Ordinary fully paid shares and quoted options.

Number of \*securities issued or to be issued (if known) or maximum number which may be issued 29,179,982 quoted ordinary shares and options.

- Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- 1. 19,453,313 ordinary shares under a two for five entitlement issue; and
- 2. 9,726,669 options to purchase ordinary shares at an exercise price of \$0.27 exercisable by 25 November 2018.

<sup>+</sup> See chapter 19 for defined terms.

Yes, the shares (and the shares issued on Do the \*securities rank equally in 4 exercise of the options) will rank equally in all respects from the +issue date with an existing +class of quoted all respects from the issue date. +securities? If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution interest payment \$0.175 per share and nil consideration for the Issue price or consideration 5 options Purpose of the issue Development of the company's asset OPT-6 (If issued as consideration for the 302 to the completion of Phase I and IIa acquisition of assets, clearly clinical trials. (Refer to ASX announcement identify those assets) dated 6 October 2014 for further details). Not applicable 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder Not applicable resolution under rule 7.1A was passed Not applicable 6c Number of \*securities issued without security holder approval under rule 7.1 6d Not applicable Number of \*securities issued with security holder approval under rule 7.1A

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Not applicable	
6f	Number of *securities issued under an exception in rule 7.2	Not applicable	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	Not applicable	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Not applicable	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	five entitlement iss November 2014; and	under the entitlement
		Number	+Class
8	Number and +class of all +securities quoted on ASX	74,943,471	Ordinary

<sup>(</sup>including the \*securities in section 2 if applicable)

Number	<sup>+</sup> Class
74,943,471	Ordinary
	,
9,726,669	Quoted options
	-

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	+Class
Not applicable	Not applicable

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The ability of the Company to offer dividends (if any) is contingent on it making taxable profits. The determination of any dividend payable is at the absolute discretion of the Directors.

#### Part 2 - Pro rata issue

11	Is security holder approval required?	No
12	Is the issue renounceable or non-renounceable?	Non-renounceable
13	Ratio in which the *securities will be offered	Two for every five existing ordinary shares held
14	*Class of *securities to which the offer relates	Ordinary shares
15	<sup>+</sup> Record date to determine entitlements	15 October 2014
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable
17	Policy for deciding entitlements in relation to fractions	Rounded up to the next whole number

18 Names of countries in which the entity has security holders who will not be sent new offer documents

All countries outside Australia and New Zealand

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

19	Closing date for receipt of acceptances or renunciations	31 October 2014
20	Names of any underwriters	Bell Potter Securities Limited
21	Amount of any underwriting fee or commission	3.5% of amounts raised under the entitlement offer
22	Names of any brokers to the issue	Not Applicable
23	Fee or commission payable to the broker to the issue	Not Applicable
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not Applicable
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	17 October 2014
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not Applicable
28	Date rights trading will begin (if applicable)	3 November 2014
29	Date rights trading will end (if applicable)	10 November 2014
30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not applicable
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable

<sup>+</sup> See chapter 19 for defined terms.

32	of their e	ecurity holders dispose ntitlements (except by gh a broker)?	Not applicable
33	<sup>+</sup> Issue date	2	12 November 2014
		tion of securities	blying for quotation of securities
34	Type of *some)	ecurities	
(a)	+Sec	curities described in Part	.1
(b)	Exan	oyee incentive share securities who	nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entitie	s that hav	e ticked box 34(a)	
Additi	onal secu	rities forming a new	class of securities
Tick to docume	_	are providing the informat	ion or
35	add		securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36	+sec 1 - 1 1,00 5,00 10,0		r securities, a distribution schedule of the additional umber of holders in the categories
37	A co	ppy of any trust deed for	the additional *securities

38	Number of *securities for which *quotation is sought	Not applicable	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	Not applicable	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Not applicable	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	Not applicable	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number Not applicable	<sup>+</sup> Class Not applicable

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:		12 November 2014 Date:
orgii ilere.	(Company secretary)	
Print name:	Mike Tonroe	

== == == ==

11 del

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exc	eeding 15% of capital
Step 1: Calculate "A", the base fig capacity is calculated	ure from which the placement
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	
Add the following:	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period	
Note:  Include only ordinary securities here — other classes of equity securities cannot be added  Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed  It may be useful to set out issues of securities on different dates as separate line items	
Subtract the number of fully paid  †ordinary securities cancelled during that 12 month period	
"A"	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	
<ul> <li>Under an exception in rule 7.2</li> </ul>	
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1	
"A" x 0.15	
Note: number must be same as shown in Step 2	
Subtract "C"	
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.15] – "C"	[Note: this is the remaining placement capacity under rule 7.1]

Step 1: Calculate "A", the base fig capacity is calculated	gure from which the placement
"A" Note: number must be same as shown in	
Step 1 of Part 1  Step 2: Calculate 10% of "A"	
"D"	0.10  Note: this value cannot be changed
<b>Multiply</b> "A" by 0.10	
7.1A that has already been used  Insert number of +equity securities issued or agreed to be issued in that 12 month	t of placement capacity under rule
period under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A						
"A" x 0.10						
Note: number must be same as shown in Step 2						
Subtract "E"						
Note: number must be same as shown in Step 3						
<i>Total</i> ["A" × 0.10] – "E"						
	Note: this is the remaining placement capacity under rule 7.1A					

CLASS: FP /ORDINARY FULLY PAID SHARES  NAME AND ADDRESS	UNITS	% I/C	RANK
BNP PARIBAS NOMS PTY LTD <drp></drp>	13,486,971	18.00	1
CITICORP NOMINEES PTY LIMITED	9,747,362	13.01	2
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	7,904,998	10.55	3
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD	3,122,090	4.17	4
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED-GSCO ECA	2,109,187	2.81	5
CAPITAL MACQUARIE PTY LIMITED	1,928,304	2.57	6
J P MORGAN NOMINEES AUSTRALIA LIMITED	1,924,479	2.57	7
4 EYES LIMITED <worsley a="" c="" family=""></worsley>	1,643,550	2.19	8
CHEMICAL TRUSTEE LIMITED	1,158,108	1.55	9
TRADERS MACQUARIE PTY LIMITED	907,161	1.21	10
NATIONAL NOMINEES LIMITED	762,732	1.02	11
JFF STEVEN PTY LTD	714,867	0.95	12
DR CHOON-JOO KHO	686,000	0.92	13
PHILADELPHIA INVESTMENTS PTY LTD	653,859	0.87	14
PRIMDONN NOMINEES PTY LIMITED <primdonn ac="" securities="" sf=""></primdonn>	650,000	0.87	15
PHILADELPHIA INVESTMENTS PTY LTD	509,385	0.68	16
ABN AMRO CLEARING SYDNEY NOMINEES PTY LTD <custodian a="" c=""></custodian>	505,914	0.68	17
MR DAVID JOHN MASSEY <the a="" c="" d="" j="" massey="" super=""></the>	493,822	0.66	18
MR ROBERT JOHN KLUPACS	480,453	0.64	19
FORSYTH BARR CUSTODIANS LTD <forsyth a="" barr="" c="" ltd-nominee=""></forsyth>	406,507	0.54	20
*** REPORT TOTAL ***  *** REMAINDER ***	49,795,749 25,147,722		
*** GRAND TOTAL ***	74,943,471 =========		

CLASS: OPT/LIST OPT EXP 25/ NAME AND ADDR	•	UNITS	% I/C	RANK
CITICORP NOMI	NEES PTY LIMITED	2,657,755	27.32	1
BNP PARIBAS N <drp></drp>	OMS PTY LTD	2,416,029	24.84	2
J P MORGAN NO LIMITED	MINEES AUSTRALIA	942,083	9.69	3
CAPITAL MACQU	ARIE PTY LIMITED	275,472	2.83	4
4 EYES LIMITE <worsley fami<="" td=""><td></td><td>234,793</td><td>2.41</td><td>5</td></worsley>		234,793	2.41	5
CAPITA TRUSTE <mk p<="" pension="" td=""><td>ES LIMITED LAN-473278 A/C&gt;</td><td>187,517</td><td>1.93</td><td>6</td></mk>	ES LIMITED LAN-473278 A/C>	187,517	1.93	6
PHILADELPHIA PTY LTD	INVESTMENTS	186,405	1.92	7
PHILADELPHIA LTD	INVESTMENTS PTY	145,218	1.49	8
ABN AMRO CLEA NOMINEES PTY <custodian <="" a="" td=""><td>LTD</td><td>143,000</td><td>1.47</td><td>9</td></custodian>	LTD	143,000	1.47	9
TRADERS MACQU	ARIE PTY LIMITED	129,595	1.33	10
HSBC CUSTODY (AUSTRALIA) L		128,972	1.33	11
M F M PROPERT	IES PTY LIMITED	112,510	1.16	12
PHILADELPHIA LTD	INVESTMENTS PTY	110,509	1.14	13
MR SIMON ROBE	RT EVANS	98,446	1.01	14
ACCBELL NOMIN	EES PTY LTD	93,759	0.96	15
MR IAN CHARLE MRS ERICA ANN		72,860	0.75	16
MR DAVID JOHN <the d="" j="" mass<="" td=""><td>MASSEY EY SUPER A/C&gt;</td><td>70,546</td><td>0.73</td><td>17</td></the>	MASSEY EY SUPER A/C>	70,546	0.73	17
DR MARC GREGO	RY ACHEN	66,000	0.68	18
MR MICHAEL RI <tarant super<="" td=""><td></td><td>48,000</td><td>0.49</td><td>19</td></tarant>		48,000	0.49	19
MR GRAHAM COU	RTNEY CHARLES	47,500	0.49	20

***		TOTAL INDER	***	8,166,969 1,559,700	
***	GRAND	TOTAL	***	9,726,669 ======	100.00

EDEN

	1	1001	5001	10001	100001	* TOTAL *
	to	to	to	to	to	
	1000	5000	10000	100000	(MAX)	
FP	/ORDINA	RY FULLY PAI	D SHARES			
Holders						
Issuer	145	348	96	73	18	680
Chess	322	754	254	336	38	1704
Total	467	1102	350	409	56	2384
Units						
Issuer	127025	900362	730881	1927715	10772359	14458342
Chess	261545	2039368	1984745	10238881	45960590	60485129
Total	388570	2939730	2715626	12166596	56732949	74943471

TOTAL HOLDERS FOR CLASSES SELECTED 2384

TOTAL UNITS " " " 74943471

	1	1001	5001	10001	100001	* TOTAL *
	to	to	to	to	to	
	1000	5000	10000	100000	(MAX)	
OPT	/LIST OP	T EXP 25/11/	18 @ \$0.27			
Holders						
Issuer	59	25	11	4	5	104
Chess	176	111	45	36	8	376
Total	235	136	56	40	13	480
Units						
Issuer	29645	60467	75518	104034	847199	1116863
Chess	86545	295835	324528	1080239	6822659	8609806
Total	116190	356302	400046	1184273	7669858	9726669

TOTAL HOLDERS FOR CLASSES SELECTED

480

TOTAL UNITS " " "

9726669